Moreover, our findings strongly suggest that histopathological evaluation of CD137 in various pathological tissue lesions, regardless of anatomical distribution or tissue origins, can be a critical method for oncologists to predict tumor response assessment and effectively monitor the response to immunologic treatments. This evidence concerns the gene TNFRSF9 and neoplasm.